Stewardship / Resistance Scan for Sep 06, 2017

Precision antimicrobials
;
Money for antibiotic development
;
Canada AMR framework
;
Pharmacist stewardship

Precision antimicrobial drug candidate has added benefits, study finds

A team of scientists in the United States and the United Kingdom have identified additional benefits in a new class of antibacterial compounds that specifically kill Clostridium difficile strains without disrupting beneficial bacteria in the gut, according to a study today in Science Translational Medicine.

The compounds, called Avidocin-CDs, have previously been shown to kill specific C difficile strains, including the hypervirulent ribotype 027, and prevent them from colonizing mice. Avidocin-CDs work by attaching to the outer membrane of C difficile bacteria and poking holes in it. Their ability to kill C difficile while sparing beneficial gut bacteria has made them a potential candidate for further development as a human therapeutic. Broad-spectrum antibiotics currently used to treat C difficile are problematic because they wipe out good gut bacteria, which can leave patients at risk for recurrent infections.

In this study, further exploration of Avidocin-CDs showed that the compounds specifically bind to a crucial component of a protective protein shell called the S-layer. With that information in hand, the scientists were able to develop a panel of Avidocin-CDs with killing activity in vitro against 60 different C difficile clinical isolates encompassing all 12 known S-layer types. But the scientists found that the compounds have an additional advantage. While mutations caused some of the C difficile bacteria to lose their S-layers and become resistant to the Avidocin-CDs, there was a trade-off: In hamster models, Avidocin-CD-resistant bacteria produced less toxin, fewer spores, and were less virulent.

"The precise killing activity of Avidocin-CDs makes them attractive agents for both treatment and prevention because they can be administered to patients without altering the diversity of the complex gut microbiota," the authors write. "In addition, when resistance does emerge, Avidocin-CDs force the pathogen to sacrifice virulence for viability, making the potential clinical impact of resistance inconsequential."
Sep 6 Sci Transl Med study

 

Nations pledge millions for new antibiotic development

Led by Germany, a handful of nations and foundations have pledged 56.5 million euros ($65.7 million US) to the Global Antibiotic Research & Development Partnership (GARDP) to develop new treatments for antibiotic resistant infections.

The money, pledged during a GARDP fundraising event in Berlin, will support drug development in GARDP's four program areas: New treatments for sexually transmitted infections, with a focus on drug-resistant gonorrhea; Antimicrobial memory recovery, which aims to use knowledge from abandoned antibiotic development projects to help identify new drug opportunities; New treatment regimens for neonatal sepsis; and new antibiotics specifically adapted for children.

The bulk of the money was pledged by Germany (51.35 million euros), with smaller contributions from the Netherlands, Switzerland, South Africa, Luxembourg, the United Kingdom, and the UK-based Wellcome Trust.

"With this support we can take concrete strides in making our vision a reality, reaching our goal of delivering up to four new treatments by 2023, and striving to improve the lives of all patients who need affordable and effective new antibiotics," GARDP president Manica Balasegaram, MRCP, MSc, said in a press release.

GARDP was established in 2016 by the World Health Organization and the Drugs for Neglected Diseases initiative.
Sep 4 GARDP press release


Canada releases antimicrobial resistance framework

Canada yesterday released a nationwide framework to spearhead a coordinated effort from all levels of government and across all sectors—including public health, healthcare, animal health, agriculture, industry, and academia—to address antimicrobial resistance (AMR), according to a Health Canada press release.

"Antimicrobial resistance is a serious global health threat that cannot be overlooked," said Minister of Health Ginette Petitpas. "Our government is committed to taking action to mitigate the impact of antimicrobial resistance on Canadians. We are enhancing surveillance, promoting good infection prevention and control practices, promoting the responsible use of antimicrobials, and supporting research and innovation for new prevention and treatment products."

Minister of Agriculture and Agri-Food Lawrence MacAulay added, "The prudent use of antimicrobials is an important issue involving not only human health, but the health of animals, food safety, environment and the economy. Agriculture must play an important role in containing the development and spread of antimicrobial resistance."

The Pan-Canadian Framework, as it is called, builds on the AMR work that is already under way in human and animal health sectors and strives to connect various efforts across the country, Health Canada said in the report. "The Framework provides the foundation to spur further action and collaboration among partners in human and animal sectors to minimize the impact of AMR, and to ensure that antimicrobials will continue to be an effective tool in protecting the health of Canadians."
Sep 5 Health Canada news release
Sep 5 Health Canada report

 

UK pharmacy group details steps to better antimicrobial stewardship

Declaring, "Pharmacist expertise and clinical knowledge must be fully utilised to ensure appropriate use of antibiotics and improve stewardship" to reduce AMR, the UK Royal Pharmaceutical Society (RPS) this week published a policy report and related antimicrobial stewardship quick reference guide geared toward pharmacists.

The policy document focuses on pharmacists' role as part of a multidisciplinary approach in tackling the challenges of inappropriate use of antibiotics. The recommendations in the policy are geared toward helping the country reach its goal of reducing inappropriate antibiotic prescribing by 50% by 2020.

The policy report and quick reference guide, aim to complement recommendations made by the Pharmaceutical Group of the European Union and the International Pharmaceutical Federation in the global fight against AMR, according to the RPS.

The six policy recommendations focus on (1) pharmacist leadership, (2) multidisciplinary teams, (3) pharmacist access to the patient health record, (4) public awareness, (5) further research, and (6) education and training for pharmacists.
Sep 3 RPS policy report
Sep 3 RPS quick reference guide

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»